T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rivian
RIVN
|
+$18.7B |
| 2 |
Apple
AAPL
|
+$5.48B |
| 3 |
NVIDIA
NVDA
|
+$5.33B |
| 4 |
Tesla
TSLA
|
+$4.47B |
| 5 |
Microsoft
MSFT
|
+$2.15B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$4.26B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.3B |
| 3 |
Morgan Stanley
MS
|
+$2.82B |
| 4 |
Global Payments
GPN
|
+$2.43B |
| 5 |
PayPal
PYPL
|
+$2B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.4% |
| 2 | Healthcare | 16.1% |
| 3 | Consumer Discretionary | 15.8% |
| 4 | Communication Services | 12.38% |
| 5 | Financials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2026
Silgan Holdings
SLGN
$4.41B
| $1.02M | ﹤0.01% |
23,808
-1,403
| -6% | -$57.9K |
|
2027
Glaukos
GKOS
$11.1B
| $1.02M | ﹤0.01% |
22,925
-687
| -3% | -$31.7K |
|
|
DVAX
2028
DELISTED
Dynavax Technologies
DVAX
| $1.02M | ﹤0.01% |
72,329
+29,014
| +67% | +$477K |
|
2029
Cardlytics
CDLX
$24.9M
| $1.01M | ﹤0.01% |
1,530
-47
| -3% | -$35.9K |
|
2030
Sonos
SONO
$2B
| $1.01M | ﹤0.01% |
33,858
-4,952
| -13% | -$157K |
|
|
DOOR
2031
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $1.01M | ﹤0.01% |
8,556
-924
| -10% | -$106K |
|
|
AVTA
2032
DELISTED
Avantax, Inc. Common Stock
AVTA
| $1.01M | ﹤0.01% |
58,257
-13,120
| -18% | -$223K |
|
2033
Oscar Health
OSCR
$10B
| $1.01M | ﹤0.01% |
128,316
-24,828
| -16% | -$312K |
|
|
PENG
2034
Penguin Solutions Inc
PENG
$3.26B
| $1.01M | ﹤0.01% |
28,354
-178,572
| -86% | -$5.07M |
|
|
FLNA
2035
Filana Therapeutics
FLNA
$44.7M
| $1M | ﹤0.01% |
22,901
+1,639
| +8% | +$85.9K |
|
|
BRG
2036
DELISTED
Bluerock Residential Growth REIT, Inc.
BRG
| $995K | ﹤0.01% |
37,700
-5,200
| -12% | -$82.5K |
|
2037
Senti Biosciences Holdings
SNTI
$13.7M
| $993K | ﹤0.01% |
10,067
-289,933
| -97% | -$28.9M |
|
|
NXGN
2038
DELISTED
NextGen Healthcare, Inc. Common Stock
NXGN
| $991K | ﹤0.01% |
55,702
+4,297
| +8% | +$69K |
|
|
AZEK
2039
DELISTED
The AZEK Co
AZEK
| $989K | ﹤0.01% |
21,383
-17,715
| -45% | -$705K |
|
2040
RE/MAX Holdings
RMAX
$278M
| $989K | ﹤0.01% |
32,429
+2,769
| +9% | +$84.5K |
|
|
UCTT
2041
Ultra Clean Holdings
UCTT
$4.09B
| $989K | ﹤0.01% |
17,239
-11,693
| -40% | -$608K |
|
2042
Metallus
MTUS
$905M
| $988K | ﹤0.01% |
59,897
-700
| -1% | -$10.2K |
|
2043
DMC Global
BOOM
$155M
| $987K | ﹤0.01% |
24,924
+3,065
| +14% | +$122K |
|
2044
MBIA
MBI
$258M
| $987K | ﹤0.01% |
62,530
-783
| -1% | -$10.3K |
|
2045
Cheesecake Factory
CAKE
$5.59B
| $983K | ﹤0.01% |
25,109
-1,853
| -7% | -$78K |
|
2046
Fortis
FTS
$28.8B
| $981K | ﹤0.01% |
20,301
-1
| -0% | -$45 |
|
2047
1st Source
SRCE
$2.14B
| $981K | ﹤0.01% |
19,769
-277
| -1% | -$13.5K |
|
2048
Trustmark
TRMK
$2.81B
| $980K | ﹤0.01% |
30,190
-1,111
| -4% | -$36.3K |
|
2049
Vicor
VICR
$10.8B
| $979K | ﹤0.01% |
7,706
-760
| -9% | -$108K |
|
|
HEES
2050
DELISTED
H&E Equipment Services
HEES
| $978K | ﹤0.01% |
22,085
-1,423
| -6% | -$62.1K |
|
Similar funds
T. Rowe Price Associates's Q4 2021 Portfolio in Review
As of Q4 2021, T. Rowe Price Associates held 3,121 positions worth $1.11T, up 4.6% from $1.06T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q4 2021 filing shows 186 new, 817 increased, 1,825 reduced and 148 closed positions. Its largest new stake was Rivian: 162,080,423 shares worth $16.1B. The largest sale was Visa, an estimated $4.26B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, up from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q4 2021 buy was Rivian: 162,080,423 shares worth $16.1B.
- T. Rowe Price Associates added most to Apple in Q4 2021, an estimated $5.48B increase.
- T. Rowe Price Associates's biggest Q4 2021 reduction was Visa, cutting an estimated $4.26B.
- T. Rowe Price Associates fully exited Acceleron Pharma in Q4 2021, selling an estimated $923M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $1.11T portfolio in Q4 2021.
- T. Rowe Price Associates opened 186 new positions and closed 148 in Q4 2021.
- T. Rowe Price Associates's portfolio value rose 4.6% quarter-over-quarter to $1.11T.
Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.